bluebird bio (NASDAQ:BLUE) Trading Up 12.6%
bluebird bio (NASDAQ:BLUE) Trading Up 12.6%
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating)'s share price was up 12.6% during mid-day trading on Thursday . The company traded as high as $6.76 and last traded at $6.68. Approximately 174,236 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 5,735,633 shares. The stock had previously closed at $5.93.
蓝鸟生物周四午盘股价上涨12.6%，最高报6.76美元，尾盘报6.68美元。午盘约有174,236股易手，较5,735,633股的日均成交量下跌97%。该股此前收盘报5.93美元。
Analyst Ratings Changes
分析师评级发生变化
A number of equities research analysts have recently issued reports on BLUE shares. Morgan Stanley reduced their price target on shares of bluebird bio to $3.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 17th. Barclays raised shares of bluebird bio from an "underweight" rating to an "equal weight" rating and boosted their price target for the company from $3.00 to $5.00 in a research note on Friday, August 5th. Raymond James upgraded shares of bluebird bio from a "market perform" rating to an "outperform" rating and set a $8.00 price objective for the company in a report on Tuesday, August 2nd. Finally, Wedbush dropped their price objective on shares of bluebird bio from $10.00 to $8.00 and set a "neutral" rating for the company in a report on Tuesday, May 10th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $10.50.
一些股票研究分析师最近发布了关于蓝股的报告。5月17日，周二，摩根士丹利在一份研究报告中将蓝鸟生物的目标价下调至3.00美元，并对该股设定了“减持”评级。8月5日，巴克莱在一份研究报告中将蓝鸟生物的股票评级从减持上调至同等权重，并将该公司的目标价从3.00美元上调至5.00美元。雷蒙德·詹姆斯在8月2日(周二)的一份报告中将蓝鸟生物的股票评级从“市场表现”上调至“跑赢大盘”，并为该公司设定了8.00美元的目标价。最后，韦德布什在5月10日周二的一份报告中将蓝鸟生物公司的股票目标价从10.00美元下调至8.00美元，并将该公司的评级定为中性。两位投资分析师对该股的评级为卖出，九位给予持有评级，两位给予买入评级，一位给予该公司强烈的买入评级。根据MarketBeat.com的数据，该公司目前的平均评级为持有，共识目标价为10.50美元。
bluebird bio Trading Up 8.4 %
蓝鸟生物交易上涨8.4%
The company has a market cap of $495.88 million, a price-to-earnings ratio of -0.79 and a beta of 1.29. The firm's fifty day simple moving average is $4.39 and its 200 day simple moving average is $4.77.
该公司市值为4.9588亿美元，市盈率为-0.79倍，贝塔系数为1.29。该公司的50日简单移动均线为4.39美元，200日简单移动均线为4.77美元。
Insider Activity
内幕活动
In other news, CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Jason Cole sold 7,448 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $32,696.72. Following the completion of the transaction, the insider now owns 203,740 shares of the company's stock, valued at approximately $894,418.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,364 shares of company stock worth $146,664. Corporate insiders own 2.90% of the company's stock.
其他消息方面，首席执行官安德鲁·奥本辛在8月4日(星期四)的一次交易中出售了21,805股公司股票。这些股票的平均价格为4.39美元，总价值为95,723.95美元。交易完成后，首席执行官现在拥有该公司247,131股，价值约1,084,905.09美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过以下链接获得。其他消息方面，首席执行官安德鲁·奥本辛在8月4日(星期四)的一次交易中出售了21,805股公司股票。这些股票的平均价格为4.39美元，总价值为95,723.95美元。交易完成后，首席执行官现在拥有该公司247,131股，价值约1,084,905.09美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过以下链接获得。此外，内部人士杰森·科尔在8月4日星期四的一次交易中出售了7,448股该公司股票。这些股票以4.39美元的平均价格出售，总成交金额为32,696.72美元。交易完成后，这位内部人士现在拥有203,740股该公司股票，价值约894,418.60美元。此次拍卖的披露信息可在此处找到。上个季度，内部人士出售了34,364股公司股票，价值146,664美元。企业内部人士持有该公司2.90%的股份。
Institutional Trading of bluebird bio
蓝鸟生物的制度性交易
Several institutional investors and hedge funds have recently bought and sold shares of BLUE. Duality Advisers LP raised its position in bluebird bio by 19.3% in the 4th quarter. Duality Advisers LP now owns 62,344 shares of the biotechnology company's stock valued at $623,000 after purchasing an additional 10,070 shares during the last quarter. Advisor Group Holdings Inc. raised its position in bluebird bio by 24.4% in the 4th quarter. Advisor Group Holdings Inc. now owns 18,058 shares of the biotechnology company's stock valued at $180,000 after purchasing an additional 3,543 shares during the last quarter. Toronto Dominion Bank purchased a new stake in bluebird bio in the 4th quarter valued at $1,426,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in bluebird bio by 145.1% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 26,363 shares of the biotechnology company's stock valued at $279,000 after purchasing an additional 15,609 shares during the last quarter. Finally, Northern Trust Corp raised its position in bluebird bio by 0.3% in the 4th quarter. Northern Trust Corp now owns 719,985 shares of the biotechnology company's stock valued at $7,193,000 after purchasing an additional 2,348 shares during the last quarter. Hedge funds and other institutional investors own 96.38% of the company's stock.
几家机构投资者和对冲基金最近买卖了Blue的股票。Duality Advisers LP在第四季度将其在蓝鸟生物的头寸提高了19.3%。Duality Advisers LP现在拥有这家生物技术公司62,344股票，价值623,000美元，在上个季度又购买了10,070股票。Advisor Group Holdings Inc.在第四季度将其在蓝鸟生物的持仓提高了24.4%。Advisor Group Holdings Inc.现在持有这家生物技术公司18,058股股票，价值18万美元，上个季度又购买了3,543股。多伦多道明银行在第四季度购买了蓝鸟生物的新股份，价值1,426,000美元。三菱日联国赛资产管理有限公司在第四季度将其在蓝鸟生物的持仓提高了145.1%。三菱UFJ国赛资产管理有限公司在上个季度增持了15,609股后，现在持有26,363股这家生物技术公司的股票，价值27.9万美元。最后，北方信托公司在第四季度将其在蓝鸟生物的头寸提高了0.3%。北方信托公司现在拥有719,985股生物技术公司的股票，价值7,193,000美元，在上个季度又购买了2,348股。对冲基金和其他机构投资者持有该公司96.38%的股票。
About bluebird bio
关于蓝鸟传记
(Get Rating)
(获取评级)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
蓝鸟生物公司是一家生物技术公司，研究、开发和商业化针对严重遗传病的变革性基因疗法。其用于治疗严重遗传性疾病的候选产品包括用于治疗输血依赖型β-地中海贫血的贝替贝吉基因Autotemcel；用于治疗镰状细胞病(SCD)的lovotieglogene autemcel；以及用于治疗大脑肾上腺脑白质营养不良的伊利伐多烯Autotemcel。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 3 Stable Growth Stocks for Bumpy Times
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- 免费获取StockNews.com关于蓝鸟生物的研究报告(蓝色)
- 找到并获利于52周低点的股票交易
- 迪士尼(NYSE：DIS)的股票刚刚给了投资者一个巨大的信号
- 清洁能源法案通过后，太阳能股大放异彩
- 颠簸时代的3只稳定成长股
- 大型和小型石油和天然气类股盈利后反弹
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
获得蓝鸟生物日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对蓝鸟生物和相关公司的最新新闻和分析师评级的每日简明摘要。